The peptide exhibits efficacy across various administration routes including local application at the injury site, systemic intramuscular injection, and oral delivery
Complete product details, current pricing, and terms are available by viewing the current ProHealth BPC-157 offer (official ProHealth page)
By 2008, the manufacturer (Palatin Technologies) halted nasal formulation trials and pivoted to a subcutaneous injection route, which showed fewer cardiovascular side effects
DIM is an essential part of BHRT "pellet" therapy
No toxic or lethal dose was achieved across a remarkably wide range of doses from 0.006 mg/kg to 20 mg/kg
BPC-157 is further shown to have powerful anti-inflammatory effects throughout the GI tract and systemically, lending it potential in the treatment of inflammatory and metabolic diseases [2, 3, 4, 5, 6]